For people with depression who are so-called ‘treatment-resistant’ – meaning they do not respond to known medicines – there are very few treatment options. One of the substances with antidepressant effects that it is hoped will soon be available for clinical use is psilocybin, a compound found in certain fungi (‘magic mushrooms’). The substance has already proven its effectiveness, but it is only partially understood exactly how the active ingredient works in the brain. A British research team has now investigated this further. They analysed MRI brain scans of 59 people with depression who had taken part in two psilocybin studies. The first study involved participants who knew they had received psilocybin. In the second, the study participants received either antidepressants (SSRIs) or psilocybin as part of a double-blind trial. The analysis showed that psilocybin treatment can also be detected in the brain and manifests as increased connectivity between specific brain regions. This ‘rewiring’ correlated with an improvement in symptoms among the participants and freed them from unnecessary rumination and excessive self-focus – they proved to be more emotionally stable and demonstrated improved cognitive functions. Both behavioural changes and changes in the brain were still evident three weeks after the last dose of psilocybin. It is thought that psilocybin binds to overactive receptors, temporarily disrupting brain connections and forcing them to reform in new ways. However, it is not yet clear how long this effect lasts. The scientists also warn against premature self-medication with mushrooms. Reference: Imperial College London, Increased global integration in the brain after psilocybin therapy for depression, Nature Medicine 2022; https://www.nature.com/articles/s41591-022-01744-z
How does psilocybin work in the treatment of depression?